Deliver Your News to the World

Fisher Biosciences unit, Cellomics, and Evotec Technologies Sign License Agreement


Companies to collaborate on cell-biology solutions for life-science markets.

PITTSBURGH, Pa., and HAMBURG, Germany, Jan. 30, 2006 – Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH announced today that they have entered into a worldwide, non-exclusive patent license agreement. The agreement will provide Evotec Technologies with Cellomics’ core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.
Evotec Technologies and Cellomics are also collaborating to develop and market combined offerings incorporating Cellomics’ and Evotec Technologies’ products as seamless solutions. This offering will enable cell biologists to obtain the highest quality, most productive results in their drug discovery, systems biology and high content screening efforts.

We are excited to extend the application portfolio of our Opera™ platform through this partnership with Cellomics,” said Dr Günter Bauer, chief business officer at Evotec Technologies GmbH. “The combination of highest quality cell assays and highest quality automation will provide important and completely new insight into the biomolecular network of cells. Industrialized experimental strategies replace large singular efforts in the new field of systems biology and will ultimately lead to the development of new therapies for diseases.”

The two companies will improve the compatibility and integration of their software and assay products, including validation of Cellomics’ assay kits by Evotec Technologies. Additional efforts will bring two-way data flow between the complementary platforms and access to enterprise-wide data storage, management, and analysis.

Daniel J. Calvo, president of Cellomics, added “We are very pleased to partner with Evotec Technologies to expand the use of Cellomics technologies across a broader range of applications and throughput protocols. The Opera™ instrument is very complementary with our ArrayScan® HCS Reader platform. This cooperative development will enable more productive adoption of HCS by our customers, from assay development to screening to ADME/Tox.”

Financial details of the agreement were not disclosed.

About Cellomics
Cellomics, a business unit within the Fisher Biosciences group, provides complete systems for High Content Screening (HCS) and Analysis (HCA) to drug discovery and systems biology researchers. The Cellomics platform includes automated imaging instrumentation (ArrayScan and KineticScan® HCS Readers and the cellWoRxTM High Content Cell Analysis System), BioApplication image analysis software, High Content Informatics (HCiTM), and HitKit® HCS Reagent Kits, fully integrated to improve the quality and productivity of cell-based assays. Cellomics’ proprietary platforms are in use at multiple sites within the top 15 pharmaceutical companies, as well as leading biotechnology companies and academic centers throughout the world. For more information about Cellomics-brand products and services, please visit or call 412-770-2200.

About Fisher Biosciences
Fisher Biosciences, a unit of Fisher Scientific International Inc. (NYSE: FSH), manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. From fine and high-purity chemicals, clinical diagnostics, proprietary protein-research and cell-culture products, and sterile-liquid-handling systems, to innovative RNA-interference technology and high content screening, Fisher Biosciences serves scientific-research, healthcare, drug-discovery, and general industrial customers around the world.

About Evotec Technologies GmbH
Evotec Technologies GmbH (ET), subsidiary of Evotec AG, is the world’s leading provider of confocal detection devices (Opera™, Clarina™, Insight™ Cell), cell handling devices (Elektra™, Cytocon™) and ultra-High-Throughput Screening (uHTS) systems (EVOscreen®, plate::explorer™). The Company’s product portfolio is focused on high-end technologies for automated cell biology. Its outstanding expertise in detection coupled with sophisticated automation skills, integrating hardware, software and bioware modules, makes the Company a clear leader for automated cell analysis. Evotec Technologies employs 80 people, primarily at its main site in Hamburg, Germany.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.